Other Biopharmaceuticals

Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Unveils Expansion Plans in Annual Report 2025

Hikma Pharmaceuticals Signs Strategic Memorandum with M42 to Enhance Diagnostic Tools in the UAE

Hikma Pharmaceuticals announced that Wellington Management Group LLP crossed the 5% voting rights threshold on June 9, 2026. The notification details holdings through various nominee accounts and financial instruments, including equity swaps. The ultimate controlling entity is identified as Wellington Management Group LLP.

London Stock Exchange

State Street

Northern Trust

JPMorgan Chase

HSBC Holdings Plc

Goldman Sachs

State Street® US Equity Premium Inc ETF

Northern Trust Pref Share NTRSO 4.7 Perp 01/01/25 E

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

HSBC 5xShortSG241213

HSBC HOLDINGS

HSBC

GS Hldg R

REG - Hikma Pharmaceutical - Holding(s) in Company

AMRN

The US Supreme Court ruled against Amarin (AMRN) in a patent dispute regarding its drug Vascepa. The Court determined that Amarin failed to prove generic manufacturer Hikma Pharmaceuticals actively induced infringement of two patents after Hikka received approval for a 'skinny-label' generic version. Consequently, Amarin's complaint was dismissed. Amarin expressed disappointment and stated it is evaluating next steps while remaining committed to its mission.

Fidelity

Amarin

Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News

StockTitan

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News

Hikma Pharmaceuticals has executed a $250 million share buyback, repurchasing 388,189 shares between May 5-8, 2026, at prices ranging from 1,402.5 to 1,445 pence per share. This buyback aims to reduce the share count, enhancing earnings per share and capital returns for investors. Since February, Hikma has bought back 5,735,311 shares for £73.7 million. Following the latest buyback, the company will have 216,151,142 shares in issue. Analysts rate HIK stock as a Buy with a £1870.00 price target, though some concerns about cash generation and technical trends persist.

Tip Ranks

Hikma Advances $250m Buyback, Tightening Share Count

Hikma Pharmaceuticals Plc(HIK.UK)

REG - Hikma Pharmaceutical - Holding(s) in Company

Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News

Hikma Advances $250m Buyback, Tightening Share Count